Experience
Nippon Shinyaku Co., Ltd.
Sarepta Therapeutics, Inc.
Representing Sarepta Therapeutics, Inc. and its licensor The University of Western Australia in patent litigation relating to nucleic acid therapies for treatment of Duchenne muscular dystrophy (DMD).
Nippon Shinyaku Co., Ltd. v. Sarepta Therapeutics, Inc., 1:21-cv-01015, D. Del., Judges Hall, Williams
Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al.
Sarepta Therapeutics, Inc. et al.
Hartig Drug Co. Inc. v. Senju Pharmaceutical Co. Ltd.
Senju Pharmaceuticals Co. Ltd.
Advanced Micro Devices, Inc. v. S3 Graphics Co., Ltd.
S3 Graphics Co., Ltd.
Housey Pharmaceuticals, Inc. v. Otsuka Pharmaceutical Co. Ltd.
Otsuka Pharmaceutical Co. Ltd.
Koninklijke Philips NV v. Nintendo Co., Ltd.
Koninklijke Philips NV
Amarin Pharms. Ireland Ltd. v. Omthera Pharms., Inc.
Omthera Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP
NICE Ltd. et al v. CallMiner Inc.
NICE Ltd. et al
Eastman Chemical Co. v. AlphaPet, Inc.; DAK Americas LLC
Eastman Chemical Co.
Senju Pharmaceutical Co., Ltd. v. Apotex Inc.
Senju Pharmaceutical Co., Ltd.; Bausch + Lomb Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.